At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma
In Brief
A Phase 3 clinical trial evaluating Tislelizumab, Paclitaxel, and 2 other interventions for Esophageal Squamous Cell Carcinoma (ESCC). Completed, enrolled 512 participants across 104 sites in 11 countries.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Study Details
Timeline
Interventions
200 mg administered intravenously (IV)
135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
125 mg/m\^2 administered IV